GlassScriptPhysician profile
Mark S Robson
NPI 1861467904
$3,901.35
in general payments reported to CMS, 2019-2025
29 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $54.39 · 2021: $347 · 2022: $194 · 2023: $1,345 · 2024: $863 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.24 |
| Travel and Lodging | $466.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,116.83 | 2019-2025 | Prostep, Ortholoc 3di, Ortholoc 2 Lapifuse |
| Abbvie INC. | $399.93 | 2023-2025 | Dalvance |
| Treace Medical Concepts, INC. | $194.48 | 2022-2025 | |
| Abbott Laboratories | $121.11 | 2022-2025 | Proclaim, Protg |
| Amgen INC. | $105.44 | 2024-2025 | Krystexxa |
| Anika Therapeutics, INC. | $101.34 | 2022-2023 | Tactoset, Toe Motion, Twist |
| Paratek Pharmaceuticals, INC. | $67.01 | 2024-2025 | Nuzyra |
| Ossio INC | $66.79 | 2023 | |
| Convatec INC. | $61.56 | 2023-2024 | |
| Depuy Synthes Sales INC. | $57.41 | 2024-2025 | |
| Orthofix Medical, INC. | $57.24 | 2019-2021 | |
| Medtronic, INC. | $56.04 | 2023 | Intellis Adaptivestim, Vanta Adaptivestim |
| Kerecis Limited | $52.63 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Nevro Corp. | $45.08 | 2023 | Senza |
| Grt US Holding, INC. | $44.41 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $43.96 | 2020-2023 | Renasys Go V2 Home |
| Ermi LLC | $39.35 | 2023-2024 | |
| Triad Life Sciences INC. | $35.07 | 2021 | |
| Integra Lifesciences Corporation | $33.87 | 2022-2025 | Medihoney, Biodfactor, Biodrestore |
| Bone Support INC. | $32.13 | 2025 | Cerament G, Ceramentbone Void Filler |
| Mimedx Group, INC. | $31.39 | 2024 | |
| Reddress USA, INC. | $26.20 | 2024 | |
| Organogenesis INC. | $24.23 | 2024 | Affinity |
| Heron Therapeutics, INC. | $21.54 | 2021 | |
| Horizon Therapeutics Plc | $18.48 | 2021 | |
| Acera Surgical, INC. | $18.08 | 2025 | Restrata Wound Matrix |
| Tactile Systems Technology INC | $17.10 | 2021 | |
| Davol INC. | $12.65 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.